# Switchpoint Bio funding rounds and investors

As of 11 Nov 2026, Switchpoint Bio has raised $5.3M across 1 verified round on record; latest: $5.3 million pre-seed round, announced 10 Nov 2026.

They provide a blood-based epigenomic platform for drug developers to understand how disease and treatment affect human biology.

Website: https://www.switchpointbio.com/  
Headquarters: Helsinki and Cambridge, Massachusetts  
Page: https://fireround.dev/companies/switchpoint-bio

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-10 | Pre-seed | $5.3 million | not stated | Treehouse Delmar Investments | [switchpointbio.com](https://www.switchpointbio.com/insights/switchpoint-bio-pre-seed-funding), [tech.eu](https://tech.eu/2026/11/11/why-do-some-patients-respond-to-drugs-and-others-dont-switchpoint-bio-raises-53m-to-find-out), [eu-startups.com](https://www.eu-startups.com/2026/11/fresh-out-of-stealth-switchpoint-bio-raises-e4-75-million-to-decode-disease-and-drug-response-through-blood-tests) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.